Ceapro

Ceapro Debt/EBITDA

Delisted

The Total Debt to EBITDA Ratio of Ceapro (CZO.V) as of Oct 31, 2026 is -0.38. In the previous year, Total Debt to EBITDA Ratio was 0.46 — a change of -183.22% (lower).

Debt/EBITDA

-0.38

YoY

-183.22%

Last updated:

Total Debt to EBITDA Ratio of Ceapro is 2023 -0.38 . Total Debt to EBITDA Ratio of Ceapro was 2022 0.46 . It decreases by -183.22% lower compared to the previous year.

The Ceapro Debt/EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt/EBITDA
Date
Debt/EBITDA
Jan 1, 2016
0.41 CAD
Jan 1, 2017
0.55 CAD
Jan 1, 2018
1.60 CAD
Jan 1, 2019
-8.74 CAD
Jan 1, 2020
1.20 CAD
Jan 1, 2021
0.96 CAD
Jan 1, 2022
0.46 CAD
Jan 1, 2023
-0.38 CAD
The Ceapro Debt/EBITDA history
YEARDebt/EBITDAYoY
-0.38-183.22%
0.46-52.06%
0.96-20.19%
1.20-113.79%
-8.74-647.19%
1.60+192.68%
0.55+32.22%
0.41-64.67%
1.17-29.89%
1.67—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Ceapro Stock analysis

What does Ceapro do? Ceapro Inc is an innovative biotechnology company based in Edmonton, Canada. The company was founded in 1997 and has since specialized in the development of natural, biological ingredients from plants. It is listed on the Toronto Stock Exchange and has become a key player in the field of natural-based medicine and cosmetics in recent years. Ceapro's business model is based on the research and production of active compounds from plant-based raw materials. The company employs gentle extraction methods that preserve the effectiveness of the ingredients and enable environmentally friendly production. Ceapro collaborates closely with research and industry to ensure the best possible effectiveness and applicability of its products. The company's products are divided into various segments tailored to the needs of customers. One important segment is medicine, where Ceapro focuses on the development of herbal remedies. The company has already developed some promising products in this area, which can be used, for example, for inflammation, pain, or diabetes. Another important segment of Ceapro is cosmetics, where the company researches and produces natural ingredients for skin and hair care. These products are known for their high effectiveness, tolerability, and environmental friendliness. One of the company's most famous products is Avenanthramide, an ingredient derived from oats that offers anti-aging and anti-inflammatory properties. Ceapro also places special emphasis on the development of digestive-aid ingredients that can be used in the food industry. The company relies on plant enzymes and compounds that help support and relieve the digestive system. The use of natural ingredients ensures high tolerability and usability. Over the course of its history, Ceapro Inc has already won numerous awards and prizes that confirm the high quality of its products and the company's innovative power. For example, the company has been repeatedly honored with the Alberta Venture Fast Growth 50 Award and also received the Environmental Stewardship Award from the Edmonton Chamber of Commerce. Ceapro is not only an innovative biotechnology company specializing in the research and production of plant-based ingredients but also an important player in the fields of medicine and cosmetics. The company employs gentle extraction methods and collaborates closely with research and industry to achieve the best possible effectiveness and applicability. The different products are divided into the segments of medicine, cosmetics, and food and are known for their high effectiveness, tolerability, and environmental friendliness. Ceapro is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ceapro stock

Total Debt to EBITDA Ratio of Ceapro is -0.38 in 2023.

Total Debt to EBITDA Ratio of Ceapro changed from 0.46 to -0.38, representing a -183.22% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Debt to EBITDA Ratio Ceapro since 2006 – with annual values, charts, and detailed analysis.

Debt/EBITDA measures total debt relative to earnings before interest, taxes, depreciation, and amortization. It indicates the years needed to repay all debt from EBITDA.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Total Debt to EBITDA Ratio's Ceapro with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Ceapro

All Key Metrics — Ceapro